Olezarsen (Tryngolza)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Tryngolza be reimbursed by public drug plans for familial chylomicronemia syndrome (FCS).
• Tryngolza should only be reimbursed for adult patients with FCS in line with the Health Canada indication.
• Tryngolza should only be reimbursed if patients are diagnosed with FCS based on genetic or clinical assessments, as detailed in Table 1, and if the cost of Tryngolza is reduced. Because FCS is a rare disease, initiation and management of therapy with Tryngolza should be managed by a specialist with expertise in treating FCS. The recommended period for initial reimbursement is 6 months, followed by annual renewals thereafter. Renewal is recommended to be based on an observation of clinical benefit, as demonstrated by a reduction in fasting triglyceride levels, and no signs of substantial disease worsening that would indicate poor or nonresponse to treatment (i.e., increased rate of acute pancreatitis as judged by the treating clinician).